Brown Advisory Securities LLC boosted its stake in Amgen Inc. (NASDAQ:AMGN) by 1.7% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 12,718 shares of the medical research company’s stock after buying an additional 213 shares during the period. Brown Advisory Securities LLC’s holdings in Amgen were worth $2,087,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Camelot Portfolios LLC purchased a new position in Amgen during the first quarter valued at $1,429,000. Private Asset Management Inc. increased its position in Amgen by 117.8% in the first quarter. Private Asset Management Inc. now owns 3,591 shares of the medical research company’s stock valued at $589,000 after buying an additional 1,942 shares during the last quarter. Cadence Bank NA increased its position in Amgen by 6.2% in the first quarter. Cadence Bank NA now owns 3,376 shares of the medical research company’s stock valued at $554,000 after buying an additional 197 shares during the last quarter. Stillwater Capital Advisors LLC purchased a new position in Amgen during the first quarter valued at $202,000. Finally, Kornitzer Capital Management Inc. KS increased its position in Amgen by 70.6% in the first quarter. Kornitzer Capital Management Inc. KS now owns 38,865 shares of the medical research company’s stock valued at $6,377,000 after buying an additional 16,080 shares during the last quarter. Institutional investors own 79.53% of the company’s stock.

Amgen Inc. (NASDAQ AMGN) traded down 1.75% during trading on Thursday, reaching $170.51. The company had a trading volume of 491,032 shares. The company has a market capitalization of $124.42 billion, a PE ratio of 15.53 and a beta of 1.35. Amgen Inc. has a one year low of $133.64 and a one year high of $184.21. The firm’s 50 day moving average is $174.67 and its 200 day moving average is $167.36.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Tuesday, July 25th. The medical research company reported $3.27 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.11 by $0.16. Amgen had a return on equity of 29.85% and a net margin of 35.46%. The business had revenue of $5.81 billion for the quarter, compared to the consensus estimate of $5.67 billion. During the same period in the prior year, the business posted $2.84 earnings per share. The company’s quarterly revenue was up 2.1% compared to the same quarter last year. On average, equities research analysts predict that Amgen Inc. will post $12.57 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, September 8th. Shareholders of record on Thursday, August 17th will be given a dividend of $1.15 per share. The ex-dividend date is Tuesday, August 15th. This represents a $4.60 dividend on an annualized basis and a yield of 2.65%. Amgen’s dividend payout ratio (DPR) is presently 41.93%.

TRADEMARK VIOLATION NOTICE: “Brown Advisory Securities LLC Increases Stake in Amgen Inc. (AMGN)” was originally reported by Watch List News and is the property of of Watch List News. If you are reading this piece of content on another site, it was stolen and republished in violation of US & international trademark and copyright law. The original version of this piece of content can be viewed at https://www.watchlistnews.com/brown-advisory-securities-llc-increases-stake-in-amgen-inc-amgn/1470646.html.

AMGN has been the subject of several research reports. Deutsche Bank AG initiated coverage on Amgen in a research note on Friday, June 23rd. They set a “hold” rating and a $172.00 price target for the company. ValuEngine downgraded Amgen from a “buy” rating to a “hold” rating in a research note on Friday, June 2nd. Oppenheimer Holdings, Inc. set a $189.00 price target on Amgen and gave the stock a “buy” rating in a research note on Monday, June 5th. William Blair reiterated a “market perform” rating on shares of Amgen in a research note on Monday, June 26th. Finally, Robert W. Baird reiterated a “neutral” rating and set a $165.00 price target on shares of Amgen in a research note on Friday, April 28th. One analyst has rated the stock with a sell rating, twelve have assigned a hold rating, twelve have assigned a buy rating and two have assigned a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $186.64.

In other Amgen news, SVP Cynthia M. Patton sold 2,922 shares of the company’s stock in a transaction that occurred on Wednesday, May 24th. The stock was sold at an average price of $154.40, for a total transaction of $451,156.80. Following the sale, the senior vice president now directly owns 24,214 shares in the company, valued at $3,738,641.60. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Corporate insiders own 0.20% of the company’s stock.

Amgen Company Profile

Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.